OraSure Technologies Inc (OSUR) Stock Price

OSURStock

$3.78+27.33%52W

Market Cap$260.70M

P/E—

PEG Ratio6.19

Div yield—

Beta1.07

OSUR Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)22.79%

Price vs S&P 500 (4W)-8.03%

PEG Ratio6.19

VGM Score63.44

P/CF (Annual)7.82x

Book Value / Share (Quarterly)$4.51

P/TBV (Annual)0.54x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-33.29%

Cash Flow / Share (Quarterly)$-0.69

Price vs S&P 500 (YTD)45.89%

Gross Margin (TTM)42.48%

Net Profit Margin (TTM)-66.42%

EPS (TTM)$-1.04

10-Day Avg Trading Volume0.52M

EPS Excl Extra (TTM)$-1.04

Revenue Growth (5Y)-7.70%

EPS (Annual)$-0.94

ROI (Annual)-20.16%

Gross Margin (Annual)42.22%

Net Profit Margin (5Y Avg)-14.30%

Cash / Share (Quarterly)$2.55

Revenue Growth QoQ (YoY)-6.70%

ROA (Last FY)-17.05%

Revenue Growth TTM (YoY)-30.08%

EBITD / Share (TTM)$-1.00

ROE (5Y Avg)-4.68%

Operating Margin (TTM)-68.56%

Cash Flow / Share (Annual)$-0.76

P/B Ratio0.85x

P/B Ratio (Quarterly)0.66x

Net Income / Employee (Annual)$-137,500

EV / Revenue (TTM)0.79x

Net Interest Coverage (TTM)-70.76x

ROA (TTM)-18.19%

EV / EBITDA (TTM)5.17x

EPS Incl Extra (Annual)$-0.94

Current Ratio (Annual)6.58x

Quick Ratio (Quarterly)4.66x

3-Month Avg Trading Volume0.59M

52-Week Price Return27.33%

EV / Free Cash Flow (Annual)-0.10x

Revenue / Employee (TTM)$226,000

Tangible BV / Share (Quarterly)$4.24

P/S Ratio (Annual)2.31x

Asset Turnover (Annual)0.29x

52-Week High$4.58

Operating Margin (5Y Avg)-16.00%

EPS Excl Extra (Annual)$-0.94

CapEx CAGR (5Y)-32.03%

Tangible BV CAGR (5Y)-3.31%

26-Week Price Return34.04%

Quick Ratio (Annual)5.67x

13-Week Price Return16.11%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)5.46x

Enterprise Value$89.14M

Revenue / Share Growth (5Y)-9.26%

Asset Turnover (TTM)0.27x

Book Value / Share Growth (5Y)-2.73%

Revenue / Employee (Annual)$230,000

Inventory Turnover (Annual)2.04x

Pretax Margin (Annual)-56.15%

Cash / Share (Annual)$2.83

3-Month Return Std Dev53.00%

Gross Margin (5Y Avg)43.21%

Net Income / Employee (TTM)$-150,100

ROE (Last FY)-20.17%

Net Interest Coverage (Annual)-33.20x

EPS Basic Excl Extra (Annual)$-0.94

P/FCF (TTM)4.15x

Receivables Turnover (TTM)4.88x

EV / Free Cash Flow (TTM)4.96x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-1.04

Receivables Turnover (Annual)5.00x

ROI (TTM)-21.48%

P/S Ratio (TTM)2.35x

Pretax Margin (5Y Avg)-11.83%

Revenue / Share (Annual)$1.57

Tangible BV / Share (Annual)$4.57

Free OCF CAGR (5Y)117.00%

Price vs S&P 500 (52W)9.02%

Year-to-Date Return57.85%

5-Day Price Return1.87%

EPS Normalized (Annual)$-0.94

ROA (5Y Avg)-3.81%

Net Profit Margin (Annual)-59.76%

Month-to-Date Return-5.68%

Cash Flow / Share (TTM)$0.96

EBITD / Share (Annual)$-0.90

Operating Margin (Annual)-62.57%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-4.67%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-1.04

P/TBV (Quarterly)0.70x

P/B Ratio (Annual)0.51x

Inventory Turnover (TTM)1.97x

Pretax Margin (TTM)-62.24%

Book Value / Share (Annual)$4.84

Price vs S&P 500 (13W)13.32%

Beta1.07x

P/FCF (Annual)11.28x

Revenue / Share (TTM)$1.62

ROE (TTM)-21.50%

52-Week Low$2.08

vGradeA

gGradeD

mGradeB

vgmGradeB

OSUR Earnings Surprise History

Q2 25-0.19est. -0.15

Q3 25-0.13est. -0.15

Q4 25-0.19est. -0.15

Q1 26-0.24est. -0.17

Q2 26-0.20est. -0.22

OSUR Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.13

2.17

Industry Peers — Surgical & Medical Instruments(140)

Symbol	Value Score	Growth Score	Momentum Score	Price
OSUROraSure Technologies Inc	A	D	B	$3.78
SYKStryker Corporation	C	B	C	$330.59
MMM3M Company	C	D	B	$179.37
BSXBoston Scientific Corp.	C	B	D	$49.86
BDXBecton, Dickinson and Co.	B	D	B	$189.78
MDLNMedline Inc. Class A common stock	C	D	C	$35.64
RMDResMed Inc.	C	B	C	$236.59
DXCMDexCom, Inc.	D	B	B	$89.16
WSTWest Pharmaceutical Services, Inc.	D	C	B	$348.48
SOLVSolventum Corporation	C	C	B	$91.61
BAXBaxter International Inc.	B	D	B	$26.29
PENPenumbra, Inc.	D	C	C	$324.37
GMEDGLOBUS MEDICAL INC	B	B	C	$82.96
GKOSGlaukos Corporation	F	A	A	$181.39
PODDInsulet Corporation	C	A	D	$143.05
STVNStevanato Group S.p.A.	D	C	B	$22.70
TFXTeleflex Incorporated	B	F	B	$140.18
MMSIMerit Medical Systems Inc	C	B	B	$91.09
MMEDMiniMed Group, Inc. Common Stock	—	—	A	$18.92
HAEHaemonetics Corporation	C	C	A	$108.32
ICUIICU Medical Inc	C	D	B	$182.24
HTFLHeartflow, Inc. Common Stock	—	A	A	$49.89
IRTCiRhythm Holdings, Inc. Common Stock	F	A	C	$123.09
PLSEPulse Biosciences, Inc Common Stock (DE)	F	—	A	$49.00
ATRCAtriCure, Inc.	D	B	A	$48.68
UFPTUFP Technologies Inc	C	B	B	$304.21
NVCRNovoCure Limited Ordinary Shares	D	C	C	$17.62
LMATLeMaitre Vascular, Inc.	C	B	D	$78.97
INSPInspire Medical Systems, Inc.	B	B	B	$61.07
KMTSKestra Medical Technologies, Ltd. Common Stock	F	A	B	$26.92
TNDMTandem Diabetes Care, Inc.	D	C	B	$21.58
ATECAlphatec Holdings, Inc.	D	B	C	$9.33
DRTSAlpha Tau Medical Ltd. Ordinary Shares	—	—	A	$14.70
IARTIntegra LifeSciences Holdings	B	D	C	$16.79
AORTArtivion, Inc.	C	C	C	$26.38
PRCTPROCEPT BioRobotics Corporation Common Stock	C	A	D	$21.60
IRMDiRadimed Corporation	D	B	C	$87.87
BVSBioventus Inc. Class A Common Stock	B	C	A	$14.08
SGPSpyGlass Pharma, Inc. Common Stock	—	—	B	$26.60
SIBNSI-BONE, Inc. Common Stock	D	B	B	$19.54
BBNXBeta Bionics, Inc. Common Stock	D	A	A	$19.34
SSIISS Innovations International Inc. Common Stock	F	A	D	$3.55
ANGOAngioDynamics, Inc.	C	D	B	$15.95
KIDSOrthoPediatrics Corp. Common Stock	C	B	B	$24.50
MDXGMiMedx Group, Inc	C	D	C	$4.34
DCTHDelcath Systems Inc	D	B	A	$16.92
BWAYBrainsway Ltd. American Depositary Shares	F	A	C	$14.43
CERSCerus Corp	D	C	B	$2.72
TCMDTactile Systems Technology, Inc.	B	B	C	$23.58
CLPTClearPoint Neuro, Inc. Common Stock	F	A	B	$16.96
NPCENeuropace, Inc. Common Stock	D	C	C	$14.16

About OraSure Technologies Inc

OraSure Technologies manufactures oral fluid diagnostic devices and specimen collection kits for infectious disease testing. The diagnostics segment provides rapid tests for HIV and HCV, while the larger molecular solutions segment offers collection and transport kits for genetic material and infectious disease screening, including COVID-19 testing. The company generates the majority of its revenue from molecular solutions, primarily serving U.S. customers.